Loading...

David Piccioni

TitleAssistant Clinical Professor
InstitutionUniversity of California San Diego
DepartmentNeurosciences
Address9500 Gilman Drive #0819
La Jolla CA 92093
Phone858-822-6346
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 Jun 14. PMID: 29902298.
      View in: PubMed
    2. Bahrami N, Hartman SJ, Chang YH, Delfanti R, White NS, Karunamuni R, Seibert TM, Dale AM, Hattangadi-Gluth JA, Piccioni D, Farid N, McDonald CR. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics. J Neurooncol. 2018 Jun 02. PMID: 29860714.
      View in: PubMed
    3. Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni D, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. Am J Clin Oncol. 2018 Feb; 41(2):159-162. PMID: 26658237.
      View in: PubMed
    4. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni D, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 Mar 15; 124(6):1288-1296. PMID: 29211306.
      View in: PubMed
    5. Delfanti RL, Piccioni D, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N. Erratum to: Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol. 2017 Dec; 135(3):611. PMID: 28905256.
      View in: PubMed
    6. Seibert TM, Dalia Y, Karunamuni R, Piccioni D, McDonald CR, Farid N, Hattangadi-Gluth JA. Unilateral hippocampal wasting after combined-modality therapy for glioblastoma. Acta Oncol. 2018 May; 57(5):688-691. PMID: 29125006.
      View in: PubMed
    7. Bieg-Bourne CC, Millis SZ, Piccioni D, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Res. 2017 11 15; 77(22):6313-6320. PMID: 28939679.
      View in: PubMed
    8. Delfanti RL, Piccioni D, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol. 2017 Dec; 135(3):601-609. PMID: 28871469.
      View in: PubMed
    9. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni D, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. PMID: 28807936.
      View in: PubMed
    10. Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, Quan K, Zhu W, Li J, Figueroa J, Hirshman BR, Miller B, Piccioni D, Ringel F, Komotar R, Messer K, Galasko DR, Hochberg F, Mao Y, Carter BS, Chen CC. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017 Sep 15; 8(40):68769-68779. PMID: 28978155.
      View in: PubMed
    11. Saria MG, Courchesne NS, Evangelista L, Carter JL, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni D, Kesari S, Maliski SL. Anxiety and Depression Associated With Burden in Caregivers of Patients With Brain Metastases. Oncol Nurs Forum. 2017 May 01; 44(3):306-315. PMID: 28635984.
      View in: PubMed
    12. Pretanvil JA, Salinas IQ, Piccioni D. Glioblastoma in the elderly: treatment patterns and survival. CNS Oncol. 2017 Jan; 6(1):19-28. PMID: 28001088.
      View in: PubMed
    13. Schwaederle M, Husain H, Fanta PT, Piccioni D, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
      View in: PubMed
    14. McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni D, White NS, Dale AM, Farid N. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol. 2016 11; 18(11):1579-1590. PMID: 27106406.
      View in: PubMed
    15. Schwaederle M, Husain H, Fanta PT, Piccioni D, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. PMID: 26848768; PMCID: PMC4891078.
    16. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni D, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. PMID: 26873727.
      View in: PubMed
    17. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni D, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
    18. Panella L, Piccioni D, Borcescu L, Isella C, Callegari C. [A MULTIDISCIPLINARY BIOPSYCHOSOCIAL INTEGRATED APPROACH IN ORGANIZATION OF REHABILITATIVE ACTIVITY IN NURSING HOMES (RSA)]. G Ital Med Lav Ergon. 2015 Oct-Dec; 37(4):255-9. PMID: 26934811.
      View in: PubMed
    19. Saria MG, Piccioni D, Carter J, Orosco H, Turpin T, Kesari S. Current Perspectives in the Management of Brain Metastases. Clin J Oncol Nurs. 2015 Aug; 19(4):475-9. PMID: 26207714.
      View in: PubMed
    20. Alentorn A, Duran-Peña A, Pingle SC, Piccioni D, Idbaih A, Kesari S. Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther. 2015; 15(8):955-62. PMID: 26118895.
      View in: PubMed
    21. Nozawa A, Rivandi AH, Kanematsu M, Hoshi H, Piccioni D, Kesari S, Hoh CK. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes. Nucl Med Commun. 2015 Jun; 36(6):573-81. PMID: 25714806; PMCID: PMC4422715.
    22. Schwaederle M, Daniels GA, Piccioni D, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. PMID: 25852059.
      View in: PubMed
    23. Schwaederlé M, Daniels GA, Piccioni D, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748; PMCID: PMC4413635.
    24. Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni D, Kesari S. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 2015 Jan 20; 6(2):1157-70. PMID: 25528767; PMCID: PMC4359224.
    25. Schwaederle M, Daniels GA, Piccioni D, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015; 14(11):1730-7. PMID: 25928476; PMCID: PMC4614790.
    26. Piccioni D, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Oct; 16(10):1427-8. PMID: 25155359; PMCID: PMC4165427.
    27. van Vugt VA, Piccioni D, Brown BD, Brown T, Saria MG, Juarez T, Kesari S. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. CNS Oncol. 2014 Jul; 3(4):257-65. PMID: 25286037; PMCID: PMC4214215.
    28. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni D, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.
      View in: PubMed
    29. Piccioni D, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Jun; 16(6):815-22. PMID: 24627236; PMCID: PMC4022228.
    30. Piccioni D, Kesari S. Clinical trials of viral therapy for malignant gliomas. Expert Rev Anticancer Ther. 2013 Nov; 13(11):1297-305. PMID: 24138481.
      View in: PubMed
    31. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni D, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 03; 104(19):1458-69. PMID: 22945948; PMCID: PMC3529615.